Nyxoah SA Q4 2024 Earnings Conference Call: Key Highlights
On March 13, 2025, Nyxoah SA (NASDAQ: NYXH ), a leader in advanced therapeutic solutions for the treatment of sleep apnea, held its Fourth Quarter 2024 Earnings Conference Call. The call was hosted by John Landry, Chief Financial Officer, and Olivier Taelman, CEO of Nyxoah. Participants included analysts from various financial institutions:
Company Participants:
- John Landry – Chief Financial Officer
- Olivier Taelman – CEO
Conference Call Participants:
- Adam Maeder – Piper Sandler
- Jon Block – Stifel
- Matthew Park – Cantor Fitzgerald
- Suraj Kalia – Oppenheimer & Co.
- David Rescott – Baird
- Paige Chamberlain – Wolfe Research
During the call, Nyxoah’s management provided an update on their financial performance and business developments. Here are some of the key takeaways:
Financial Performance:
John Landry reported that Nyxoah had achieved record revenue growth in Q4 2024, with a 35% year-over-year increase. The company’s net loss for the quarter was $5.6 million, which was an improvement from the $7.2 million net loss in the same period the previous year. Landry attributed this improvement to a decrease in research and development expenses and an increase in product sales.
Business Developments:
Olivier Taelman discussed several business developments that contributed to the strong financial performance. These included:
- Increased market penetration in Europe, where Nyxoah’s Geneo® Wearable Hypoglossal Nerve Stimulation (HGS) device is now available in 15 countries.
- Successful launch of the Geneo® in the US, with over 1,000 units sold in Q4 2024.
- A new partnership with a leading medical device distributor in the Middle East and Africa to expand Nyxoah’s reach in those regions.
During the Q&A session, analysts asked several questions about the company’s future plans and prospects. Nyxoah’s management provided the following insights:
Future Plans:
When asked about future product development, Taelman mentioned that Nyxoah was working on a new HGS device that would be even more compact and user-friendly than the Geneo®. He also hinted at potential collaborations with other companies to expand the company’s product offerings.
Prospects:
Regarding the company’s prospects, Landry expressed optimism about Nyxoah’s growth potential, citing the large and growing market for sleep apnea treatments. He also mentioned that the company was well-positioned to benefit from the increasing trend towards home-based care and remote monitoring.
Effect on Individuals:
For individuals suffering from obstructive sleep apnea, the success of Nyxoah’s Geneo® device is promising news. The device, which uses mild electrical stimulation to keep the airway open during sleep, offers a non-invasive and effective alternative to continuous positive airway pressure (CPAP) machines. With more countries making the Geneo® available and the device gaining traction in the US, more people will have access to this life-changing technology.
Effect on the World:
The global sleep apnea market is expected to grow significantly in the coming years, driven by increasing awareness of the condition and the availability of effective treatments like Nyxoah’s Geneo® device. According to a report by Grand View Research, the market is projected to reach $26.2 billion by 2028. Nyxoah’s success in Europe and the US is a testament to the growing demand for non-invasive and user-friendly sleep apnea treatments. As the company continues to expand its reach and develop new products, it is poised to make a significant impact on the lives of millions of people worldwide.
Conclusion:
Nyxoah’s Q4 2024 Earnings Conference Call provided valuable insights into the company’s strong financial performance and promising business developments. With the successful launch of the Geneo® device in the US and increased market penetration in Europe, Nyxoah is well-positioned to capitalize on the growing demand for non-invasive and user-friendly sleep apnea treatments. The company’s future plans, including the development of a more compact and user-friendly HGS device, further underscore its commitment to innovation and growth. For individuals suffering from sleep apnea, the availability of the Geneo® device represents a significant improvement in their quality of life. For the world, Nyxoah’s success is a positive sign of the growing recognition and treatment of sleep apnea as a serious health condition.
